FDA clears Labopharm’s antidepressant

The FDA has approved Labopharm’s Oleptro extended release tablets, a once-daily formulation of the antidepressant trazodone, to treat major depressive disorder in adults. “Oleptro represents Labopharm’s second Contramid technology-based product to receive FDA approval in just over a year,” CEO James Howard-Tripp said in a statement, adding that the company  (TSX:DDS; NASDAQ:DDSS) is preparing the [...]

biotuesdays.com’s feature piece on Labopharm “in the news”

At approximately 8:00 AM ET today, this week’s feature article was posted to biotuesdays.com.  Written by Len Zehr, the piece provided Labopharm’s (TSX:DDS; NASDAQ:DDSS) CEO, James Howard-Tripp, with an opportunity to map out where his company is heading in 2010 and beyond.   In the first five hours alone, the post attracted more than 654 [...]

Labopharm’s new antidepressant to be ‘game-changer’

It’s game on for Labopharm (TSX:DDS; NASDAQ:DDSS). By February 11, the FDA is expected to approve the company’s antidepressant trazodone, a novel once-daily formulation that addresses many of the shortcomings of similar drugs on the market.  “I think it’s fair to say this drug could be a game-changer for us,” CEO James Howard-Tripp says in [...]

Labopharm inks U.K. distribution pact

Labopharm has signed an agreement with Merck Sharp & Dohme (MSD) of Britain for the distribution and marketing of Labopharm’s once-daily tramadol pain drug, Tradorec XL in England, Northern Ireland, Scotland, Wales, the Channel Islands and the Isle of Man. Under the accord with the British unit of Merck (NYSE:MRK), Labopharm will supply MSD with [...]

Labopharm files tramadol-acetaminophen drug in Europe

Labopharm (TSX:DDS) has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under a decentralized procedure (DCP) system. “Initiating the regulatory approval process in Europe builds on our recently established marketing partnership with Grenenthal GmbH,” Labopharm CEO James Howard-Tripp said in a statement. “It is our intention to commercialize our twice-daily tramadol-acetaminophen [...]

« Previous Page